Drug Approval | June 01, 2026
Zydus’ Saroglitazar wins FDA priority review after strong Phase 3 results in liver disease trial
The therapy also delivered significant improvements in key liver enzyme markers
The therapy also delivered significant improvements in key liver enzyme markers
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
These re-agent and diagnostic test kits come with 99.7% accuracy
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
